S100A2 and neoplasm: In the current study, we can only observe S100A2 cytoplasmic expression from the TMAs tumour core of CRC patients, therefore a nuclear expression of S100A2 should also be investigated in both tumour core and invasive front to understand the role of S100A2 regarding its localisation in tumour cells.